Results 41 to 50 of about 14,165 (152)

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

International Journal of Cancer, EarlyView.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner, Kai Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser‐Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group   +19 more
wiley   +1 more source

The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer

Journal of Experimental & Clinical Cancer Research
Background The cyclin D1-cyclin dependent kinases (CDK)4/6 inhibitor palbociclib in combination with endocrine therapy shows remarkable efficacy in the management of estrogen receptor (ER)-positive and HER2-negative advanced breast cancer (BC ...
Marianna Talia, Francesca Cirillo, Domenica Scordamaglia, Marika Di Dio, Azzurra Zicarelli, Salvatore De Rosis, Anna Maria Miglietta, Carlo Capalbo, Ernestina Marianna De Francesco, Antonino Belfiore, Fedora Grande, Bruno Rizzuti, Maria Antonietta Occhiuzzi, Giancarlo Fortino, Antonella Guzzo, Gianluigi Greco, Marcello Maggiolini, Rosamaria Lappano   +17 more
doaj   +1 more source

Design, Synthesis, Cytotoxicity Assessment, and Molecular Docking of Novel Triazolopyrimidines as Potent Cyclin‐Dependent Kinase 4 Inhibitors

ChemistryOpen, EarlyView.
A novel series of 1,5‐dihydro‐[1,2,4]triazolo[4,3‐a]pyrimidines (5a–g) is synthesized and evaluated as potential CDK4 inhibitors. Compounds 5c and 5d exhibit strong cytotoxicity toward HepG2 and MCF‐7 cells with IC50 ≈ 1–2 µM, comparable to doxorubicin.
Tariq Z. Abolibda, Sami A. Al‐Hussain, Basant Farag, Mohamed El‐Naggar, Magdi E. A. Zaki, Emad S. A. Alhazmi, Adel S. M. Almohammadi, Sobhi M. Gomha   +7 more
wiley   +1 more source

Synthesis of Pyrido[2,3‐d]Azolopyrimidinones: Design and Epidermal Growth Factor Receptor‐Targeted Molecular Docking Toward Novel Anticancer Leads

ChemistryOpen, EarlyView.
New pyrido[2,3‐d]azolopyrimidinones were synthesized and evaluated as potent EGFR‐targeted anticancer leads. Molecular docking and cytotoxicity studies revealed strong receptor binding and submicromolar activity, highlighting this scaffold as a promising framework for future targeted drug development.
Sobhi M. Gomha, Sami A. Al‐Hussain, Basant Farag, AbdElAziz A. Nayl, Wesam Hussein, Abdelwahed R. Sayed, Magdi E. A. Zaki   +6 more
wiley   +1 more source

Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4

Phytotherapy Research, EarlyView.
Pedunculoside targets and suppresses CDK4; consequently, it activates the MAPK pathway and inhibits hepatocellular carcinoma progression. ABSTRACT Hepatocellular carcinoma (HCC) remains a major challenge in cancer prevention and treatment, highlighting the urgent need for effective and low‐toxicity anti‐HCC therapies. Recently, CDK4‐targeted inhibitors
Yang Zhou, Jingyun Chi, Yuan Ding, Zhidi Zhang, Rui Liang, Tianhao Wang, Yan Jiang, Rujun Song, Huazhou Fu, Xizhen Zhou   +9 more
wiley   +1 more source

Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target

Cell Communication and Signaling, 2019
Background Chondrosarcoma is a malignant cartilaginous neoplasm of the bone which resistant to radiation therapy and chemotherapy. Cyclin-dependent kinase 4 (CKD4) is highly expressed in human cancer, and palbociclib, the inhibitor of CDK4 has been used ...
Zhengxiao Ouyang, Sisi Wang, Ming Zeng, Zhihong Li, Qing Zhang, Wanchun Wang, Tang Liu   +6 more
doaj   +1 more source

Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia

The FEBS Journal, EarlyView.
Genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Fortunately, menin inhibition has emerged as a promising new class of targeted therapy.
Lydia Elaine Roets, Graeme Greenfield, Katrina Mairead Lappin   +2 more
wiley   +1 more source

Pharmacokinetics, safety and tolerability of ipatasertib in combination with palbociclib and fulvestrant in patients with advanced breast cancer in a phase Ib study

Frontiers in Pharmacology
IntroductionIpatasertib is a potent, highly selective, small molecule AKT inhibitor that has been evaluated in combination with palbociclib and fulvestrant for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor two ...
Kit Wun Kathy Cheung, Ksenia Arzumanova, Victor Poon, Adam Harris, Ryan Johnson, Frauke Schimmoller, Rucha Sane   +6 more
doaj   +1 more source

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials

Cancer Medicine, 2019
Background Palbociclib is a small‐molecule, cyclin‐dependent kinase 4 and 6 inhibitor, which prevents phosphorylation of the retinoblastoma (Rb) protein and inhibits cell‐cycle progression from G1 to S phase.
Linghong Guo, Yuanyuan Hu, Xi Chen, Qingfang Li, Benling Wei, Xuelei Ma   +5 more
doaj   +1 more source